CMS Launches Medicare GLP-1 Bridge Program, Extending Access to December 2027 Amid BALANCE Model Delay
On July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) officially launched the Medicare GLP-1 Bridge program, a major temporary demonstration providing eligible Medicare Part D beneficiaries with access to select weight-loss GLP-1 receptor agonists for a flat $50 monthly copay. Following the indefinite delay of the broader Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) model (which was originally scheduled to go live in January 2027), CMS extended the Bridge program's duration from its original 6-month pilot to an 18-month run ending on December 31, 2027.
The program currently covers three weight-loss medications:
- Foundayo™ (orforglipron) — Eli Lilly's once-daily oral non-peptide GLP-1 receptor agonist
- Wegovy® (semaglutide) — Novo Nordisk's weekly subcutaneous injection
- Zepbound® KwikPen (tirzepatide) — Eli Lilly's weekly subcutaneous dual GLP-1/GIP agonist
Eligibility Estimates and Fiscal Impact
While Eli Lilly USA executives previously estimated that up to 20 million Medicare beneficiaries could meet clinical criteria for weight-loss medications, a detailed analysis by KFF suggests a much tighter eligible pool. Out of approximately 13.3 million Medicare beneficiaries with obesity or overweight, the vast majority are excluded because they have type 2 diabetes, moderate-to-severe obstructive sleep apnea (OSA), or metabolic dysfunction-associated steatohepatitis (MASH)—conditions for which GLP-1s are already covered under standard Part D benefits. After excluding these diagnoses and current GLP-1 users, the Bridge-eligible pool narrows to an estimated 3.8 million Part D enrollees.
The fiscal impact on Medicare is highly sensitive to patient uptake over the 18-month duration:
- 10% to 25% uptake: Estimated cost of $1.3 billion to $3.3 billion.
- 50% to 75% uptake: Estimated cost of $6.7 billion to $10.0 billion.
These figures reflect the negotiated net price of $245 per monthly supply (minus the patient's $50 copay) that manufacturers agreed to provide. Crucially, because these claims are processed outside the standard Part D benefit design, none of the expenditures count toward a beneficiary's gross covered drug costs or true out-of-pocket (TrOOP) spending.
Operational Architecture
CMS has tapped Humana to act as the single central processor for the Bridge program, managing prior authorizations, claims adjudication, and pharmacy payments.
- No Plan Opt-In: Part D plan sponsors do not need to opt in for their enrollees to participate.
- No Separate Pharmacy Enrollment: Pharmacies do not need to enroll separately; claims are routed electronically using a dedicated Bank Identification Number (BIN) and Processor Control Number (PCN).
- No Discount Stacking: The Bridge operates as a primary payer; manufacturer coupons and discount programs cannot be applied to Bridge claims.
This program represents a critical stopgap for older adults, but the lack of a guaranteed transition path after December 31, 2027, complicates long-term forecasting for PBMs and plan sponsors.